Diko : en:injection, interferon beta-1a, 11 mcg for subcutaneous use

en:injection, interferon beta-1a, 11 mcg for subcutaneous use

Catégories

Nom

Informations lexicales

Langue:anglais

Informations sémantiques

source:wiki

Liens externes

›

umls:C1145300

Associations d'idées

[F]

›

215

en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)

•

en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer

•

en:aneurysm minor diameter <= 5.5 cm for men

•

en:clinician documented that patient was not an eligible candidate for autogenous av fistula

•

en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c

•

en:angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed for patients with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic fun

•

en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient

•

en:12-lead electrocardiogram (ecg) performed

•

en:compounded drug, not otherwise classified

•

en:complete gene sequence analysis; msh2 gene

•

en:assessment of depression severity at the initial evaluation

•

en:anticoagulation was not ordered, reason not given

•

en:anticoagulation not ordered for reasons documented by clinician

•

en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated

•

en:aneurysm minor diameter 5.6-6.0 cm for women

•

en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory

•

en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:i intend to report the back pain measures group

•

en:aneurysm minor diameter 5.6-6.0 cm

•

en:antiplatelet medication contraindicated

•

en:cd4+ cell count or cd4+ cell percentage results documented

•

en:complete gene sequence analysis for hemochromatosis genetic testing

•

en:injection, medroxyprogesterone acetate, 50 mg

•

en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:serum creatinine test not performed, reason not given

•

en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility

•

en:pneumocystis jiroveci pneumonia prophlaxis prescribed

•

en:level of activity and symptoms not assessed

•

en:pregnancy test (urine or serum) not ordered for reasons documented by clinician

•

en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given

•

en:i intend to report the perioperative care measures group

•

en:injection, human fibrinogen concentrate, 100 mg

•

en:no anti-lipid treatment at discharge

•

en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge

•

en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit

•

en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient

•

en:aneurysm minor diameter <= 6 cm for men

•

en:aneurysm minor diameter >6cm for women

•

en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

•

en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:i intend to report the epilepsy measures group

•

en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:clinician documented that patient with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function was not an eligible candidate for angiotensin converting enzyme (ace) inhibi

•

en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:score on the writing functional communication measure at discharge was higher than at admission

•

en:genetic testing for canavan disease

•

en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)

•

en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge

•

en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:injection, testosterone enanthate, up to 100 mg administered

•

en:severity of angina assessed according to level of activity

•

en:complete gene sequence analysis; mlh1 gene

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens

•

en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:complete gene sequence analysis; brca2 gene

•

en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg

•

en:documentation of diagnosis of chronic kidney disease

•

en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record

•

en:fluocinolone acetonide, intravitreal implant

•

en:suicide risk assessed at the initial evaluation

•

en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter

•

en:patient had a medical visit in the last 6 months

•

en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission

•

en:positive airway pressure therapy not prescribed

•

en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)

•

en:most recent ldl-c not under control, results documented and reviewed

•

en:abdominal aortic aneurysm is not infarenal

•

en:beta-blocker at discharge

•

en:complete and appropriate patient data were reported to a qualified clinical database registry

•

en:beta blocker contraindicated

•

en:clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incisio

•

en:circulating tumor cell test

•

en:anti-lipid treatment at discharge

•

en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient

•

en:ldl-c was not performed

•

en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:counseling for diet and physical activity performed

•

en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

injection ▷

•

en:injection, factor viii, fc fusion protein, (recombinant), per i.u.

•

en:score on the attention functional communication measure at discharge was higher than at admission

•

en:patch closure used for patient undergoing conventional cea

•

en:injection, zoledronic acid (zometa), 1 mg administered

•

en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered

•

en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.

•

en:i intend to report the hypertension (htn) measures group

•

en:lipid profile not performed, reason not given

•

en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:injection, testosterone cypionate, up to 100 mg

•

en:adenoma(s) or other neoplasm not detected during screening colonoscopy

•

en:automated eeg monitoring

•

en:injection, testosterone enanthate, up to 200 mg administered

•

en:injection, taliglucerase alfa, 10 units

•

en:assessed level of activity and symptoms

•

en:vacuum drainage bottle and tubing for use with implanted catheter

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel

•

en:oral aspirin or other antithrombotic therapy prescribed

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis performed

•

en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)

•

en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:unlisted procedure, intestine

•

en:injection, alemtuzumab, 10 mg administered

•

en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device

•

en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason

•

en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine

•

en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given

•

en:injection, peginesatide, 0.1 mg (for esrd on dialysis)

•

en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:ldl-c not performed, reason not given

•

en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge

•

en:patient not treated for attention disorder

•

en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter

•

en:counseling for diet and physical activity not performed, reason not given

•

en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed

•

en:patients with a positive hepatitis c antibody test

•

en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes

•

en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:urine protein test was not performed, reason not given

•

en:injection, ziv-aflibercept, 1 mg

•

interféron

•

en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a

•

en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given

•

en:prescription(s) generated and transmitted via a qualified erx system

•

en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given

•

en:genetic testing for gaucher disease

•

en:injection, brentuximab vedotin, 1 mg

•

en:netupitant 300 mg and palonosetron 0.5 mg

•

en:miscellaneous supply or accessory for use with ventricular assist device

•

en:prednisone, oral, per 5 mg

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery

•

en:prostate cancer antigen 3 (pca3) testing

•

en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:no documentation of disease type, anatomic location, and activity, reason not given

•

en:injection, ocriplasmin, 0.125 mg

•

en:injection, morphine sulfate, 100mg

•

en:patient not treated for reading disorder

•

en:diabetes screening test not performed, reason not given

•

en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge

•

en:injection, sculptra, 0.1 ml

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

en:electronic wrist rotator, otto bock or equal

•

en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain

•

en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given

•

en:patient not treated for motor speech disorder

•

en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)

•

en:most recent ldl-c under control, results documented and reviewed

•

en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase

•

en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:score on the reading functional communication measure at discharge was higher than at admission

•

en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals

•

en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents

•

en:suicide risk not assessed at the initial evaluation, reason not given

•

en:score on the motor speech functional communication measure at discharge was higher than at admission

•

en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given

•

en:rehabilitation services were not ordered, reason not otherwise specified

•

en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet

•

en:patient receiving antiviral treatment for hepatitis c documented

•

en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given

•

en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given

•

en:injection, ferric carboxymaltose, 1 mg

•

en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries

•

en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes

•

en:hcpcs level ii preferred terms, obsolete

•

en:grafix prime, per square centimeter

•

en:most recent office visit diastolic blood pressure, 80 - 89 mm hg

•

en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches

•

en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy

•

en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)

•

en:i intend to report the community-acquired pneumonia (cap) measures group

•

en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:score on the spoken language expression functional communication measure at discharge was higher than at admission

•

en:pregnancy test (urine or serum) was not ordered, reason not specified

•

en:patient not treated for spoken language expression disorder

•

en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer

•

en:patient documentation - angina assessed as absent

•

en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed

•

en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)

•

en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:patient documentation - angina assessed as present

•

en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission

•

en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)

•

en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression

•

en:levonorgestrel 52mg intrauterine system

•

en:injection, sulfur hexafluoride lipid microsphere, per ml

•

en:most recent blood pressure under control

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase

•

en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given

•

en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given

•

en:patient not treated for memory disorder

•

en:injection, belinostat, 10 mg

•

en:ldl value >= 100

•

en:most recent systolic blood pressure >= 140 mm hg

•

en:injection, pertuzumab, 10 mg

•

en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score

•

en:implanted pleural catheter, each

◀

‹

214